Plant Name: Brucea javanica
Taxonomic Information:
Plant ID: NPO14948
Plant Latin Name: Brucea javanica
Taxonomy Genus: Brucea
Taxonomy Family: Simaroubaceae
Plant External Links:
NCBI TaxonomyDB:
210348
Plant-of-the-World-Online:
813610-1
Used in Medicines:
Country/Region:
Thailand; South Korea; China; IndiaTraditional Medicine System:
Indian Folk; TCM; SiddhaGeographical Distribution:
Australia; Myanmar; Indonesia; India; Cambodia; Vietnam; China; Papua New Guinea; Laos; Sri Lanka; Thailand; South Korea; Fiji; Taiwan
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; | |
| FLT3; | |
| POLA1; FUT7; | |
| CA12; CA7; CA4; | |
| PPARA; | |
| NR1H4; | |
| KDM4E; | |
| NOX4; ALOX15; TNKS; TNKS2; POLB; | |
| MMP12; | |
| HIF1A; TP53; NFKB1; | |
| LMNA; FABP3; FABP5; FABP4; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP1B1; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | POLA1 | DNA polymerase alpha subunit | P09884 | CHEMBL1828 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 5.196E-08 | 2.263E-04 | FABP3, FABP4, FABP5, FFAR4 |
| BP | GO:0009987; cellular process | GO:0009967; positive regulation of signal transduction | 3.031E-07 | 7.334E-04 | ALOX15, CYP1B1, FFAR4, FLT3, HIF1A, MMP12, NFKB1, NOX4, NR1H4, TNKS, TNKS2, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.096E-06 | 1.988E-03 | CA12, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 5.488E-06 | 4.979E-03 | FABP3, FABP4, FABP5 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.035E-05 | 6.831E-03 | CA12, CA4, CA7, MMP12, NR1H4, PPARA, TNKS, TP53 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 1.127E-05 | 6.846E-03 | TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:1902893; regulation of pri-miRNA transcription from RNA polymerase II promoter | 1.292E-05 | 7.529E-03 | HIF1A, PPARA, TP53 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.686E-05 | 8.893E-03 | CA12, CA4, CA7 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.882E-05 | 9.532E-03 | FFAR4, NFKB1, NR1H4, PPARA |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 2.144E-06 | 1.061E-04 | FABP3, FABP4, FABP5, PPARA |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.473E-06 | 1.061E-04 | CA12, CA4, CA7 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 9.922E-05 | 3.274E-03 | FLT3, TP53, HIF1A |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| C00-D49: Neoplasms | AML | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; TP53; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT3; HIF1A; TP53; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| A00-B99: Certain infectious and parasitic diseases | Viral infections | B01, B02, A60, B00, B27, G05.1, P35.2 | POLA1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; FFAR1; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; FLT3; HIF1A; TP53; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| NA: NA | GIST | NA | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; TP53; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
